Peter Smith
Direktor/Vorstandsmitglied bei RYVU THERAPEUTICS S.A.
Aktive Positionen von Peter Smith
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| RYVU THERAPEUTICS S.A. | Direktor/Vorstandsmitglied | 14.06.2023 | - |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Vorstandsvorsitzender | 17.08.2021 | - |
| Gründer | - | - | |
| Präsident | - | - | |
| Technik-/Wissenschafts-/F&E-Leiter | - | 17.08.2021 | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Berater | 01.01.2018 | - |
Amplify Medicines, Inc.
 Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| Gründer | - | - |
Karriereverlauf von Peter Smith
Ehemalige bekannte Positionen von Peter Smith
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 01.01.2011 | 31.12.2018 |
Ausbildung von Peter Smith
| Newcastle University | Doctorate Degree |
| University of Sheffield Medical School | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Vereinigtes Königreich | 3 |
| Polen | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RYVU THERAPEUTICS S.A. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Amplify Medicines, Inc.
Amplify Medicines, Inc. Pharmaceuticals: GenericHealth Technology Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Börse
- Insiders
- Peter Smith
- Erfahrung
